GSNORi (SAJE Pharma)

N/A

Report date: 2023/10/31 13:43:04
NME

Base Information

Drug NameGSNORi (SAJE Pharma)
Drug Alias NameSPL-334SPL-334.1
ClassificationSmall molecules
Mechanisms of ActionGlutathione-independent formaldehyde dehydrogenase inhibitors
TargetsGlutathione-independent formaldehyde dehydrogenase
Therapy Area/IndicationsInflammationMyocardial InfarctionIdiopathic Pulmonary Fibrosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJohns Hopkins University
China Registration ClassN/A

Develop Information

Active CompaniesSaje Pharma
Inactive CompaniesJohns Hopkins University
Active IndicationsInflammationMyocardial InfarctionIdiopathic Pulmonary Fibrosis +[4] 
Inactive IndicationsAsthma

Other Information

ATC CodeN/A
Related LinksN/A